Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2013

Open Access 01-12-2013 | Research article

Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial

Authors: Katie Jerzewski, Marc Ruel, Pierre Voisine, Michel R Le May, Alexander Kulik

Published in: Journal of Cardiothoracic Surgery | Issue 1/2013

Login to get access

Abstract

Background

Low levels of high-density lipoprotein (HDL) purportedly increase the risk after coronary bypass surgery. This may relate to the development of saphenous vein graft (SVG) disease early postoperatively, but this premise has never been evaluated in the context of a prospective trial.

Methods

The CASCADE Trial was a multi-center study of 113 patients evaluating the use of postoperative clopidogrel. Patients received standard lipid management after surgery (96% statins). At 12 months, angiography and intravascular ultrasound was performed to assess SVG occlusion and intimal hyperplasia, respectively. In this exploratory analysis, we evaluated the influence of HDL levels on the development of SVG disease at 12 months, using the established cut-off of <40 mg/dL suggesting increased risk.

Results

While HDL levels increased over the time-period of the trial (P < 0.0001), 51.1% of patients had HDL levels <40 mg/dL 12 months after surgery. Slightly more SVG occlusions occurred amongst patients with HDL levels <40 mg/dL (6.8%), compared to patients with HDL levels >40 mg/dL (4.0%, P = 0.5). With multivariate adjustment, HDL level <40 mg/dL was associated with a trend towards more SVG occlusions (odds ratio: 3.2; P = 0.12). Lower HDL level was also associated with more intimal hyperplasia on ultrasound at 12 months (P = 0.10). Patients who had HDL levels >60 mg/dL had the least amount of intimal hyperplasia, significantly less than the remainder of the cohort (P = 0.01).

Conclusions

Within this population, lower HDL levels were associated with trends towards more graft occlusions and more vein intimal hyperplasia. Modulation of postoperative HDL levels may represent a valuable future strategy for the reduction of SVG disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circ. 1998, 97: 916-931. 10.1161/01.CIR.97.9.916.CrossRef Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circ. 1998, 97: 916-931. 10.1161/01.CIR.97.9.916.CrossRef
2.
go back to reference The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med. 1997, 336: 153-162. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med. 1997, 336: 153-162.
3.
go back to reference Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M: Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011, 92: 1284-1290. 10.1016/j.athoracsur.2011.04.107. discussion 1290–1281CrossRefPubMed Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M: Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011, 92: 1284-1290. 10.1016/j.athoracsur.2011.04.107. discussion 1290–1281CrossRefPubMed
4.
go back to reference Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM: ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circ. 2011, 2011 (124): e652-e735. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM: ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circ. 2011, 2011 (124): e652-e735.
5.
go back to reference Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007, 357: 1301-1310. 10.1056/NEJMoa064278.CrossRefPubMed Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007, 357: 1301-1310. 10.1056/NEJMoa064278.CrossRefPubMed
6.
go back to reference Barter P: HDL-C: role as a risk modifier. Atheroscler Suppl. 2011, 12: 267-270. 10.1016/S1567-5688(11)70885-6.CrossRefPubMed Barter P: HDL-C: role as a risk modifier. Atheroscler Suppl. 2011, 12: 267-270. 10.1016/S1567-5688(11)70885-6.CrossRefPubMed
7.
go back to reference Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011, 365: 2255-2267.CrossRefPubMed Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011, 365: 2255-2267.CrossRefPubMed
8.
go back to reference Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009, 361: 2113-2122. 10.1056/NEJMoa0907569.CrossRefPubMed Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009, 361: 2113-2122. 10.1056/NEJMoa0907569.CrossRefPubMed
9.
go back to reference Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005, 45: 185-197. 10.1016/j.jacc.2004.10.031.CrossRefPubMed Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005, 45: 185-197. 10.1016/j.jacc.2004.10.031.CrossRefPubMed
10.
go back to reference Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: Predicting coronary heart disease in middle-aged and older persons. The Framington study. JAMA. 1977, 238: 497-499. 10.1001/jama.1977.03280060041018.CrossRefPubMed Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: Predicting coronary heart disease in middle-aged and older persons. The Framington study. JAMA. 1977, 238: 497-499. 10.1001/jama.1977.03280060041018.CrossRefPubMed
11.
go back to reference Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM: High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011, 97: 1943-1950. 10.1136/hrt.2011.225466.CrossRefPubMedPubMedCentral Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM: High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011, 97: 1943-1950. 10.1136/hrt.2011.225466.CrossRefPubMedPubMedCentral
12.
go back to reference Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL: HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circ. 2000, 102: III90-III94.CrossRef Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL: HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circ. 2000, 102: III90-III94.CrossRef
13.
go back to reference Sabik JF, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW: Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circ. 2006, 114: I454-I460.CrossRef Sabik JF, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW: Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circ. 2006, 114: I454-I460.CrossRef
14.
go back to reference Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR, Lopid Coronary Angiography Trial (LOCAT) Study Group: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circ. 1997, 96: 2137-2143. 10.1161/01.CIR.96.7.2137.CrossRef Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR, Lopid Coronary Angiography Trial (LOCAT) Study Group: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circ. 1997, 96: 2137-2143. 10.1161/01.CIR.96.7.2137.CrossRef
15.
go back to reference Kulik A, Le May M, Wells GA, Mesana TG, Ruel M: The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med. 2005, 6: 15-10.1186/1468-6708-6-15.CrossRefPubMedPubMedCentral Kulik A, Le May M, Wells GA, Mesana TG, Ruel M: The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med. 2005, 6: 15-10.1186/1468-6708-6-15.CrossRefPubMedPubMedCentral
16.
go back to reference Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M: Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circ. 2010, 122: 2680-2687. 10.1161/CIRCULATIONAHA.110.978007.CrossRef Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M: Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circ. 2010, 122: 2680-2687. 10.1161/CIRCULATIONAHA.110.978007.CrossRef
17.
go back to reference Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007, 297: 499-508. 10.1001/jama.297.5.499.CrossRefPubMed Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007, 297: 499-508. 10.1001/jama.297.5.499.CrossRefPubMed
18.
go back to reference Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007, 357: 2109-2122. 10.1056/NEJMoa0706628.CrossRefPubMed Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007, 357: 2109-2122. 10.1056/NEJMoa0706628.CrossRefPubMed
19.
go back to reference Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996, 347: 849-853. 10.1016/S0140-6736(96)91343-4.CrossRefPubMed Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996, 347: 849-853. 10.1016/S0140-6736(96)91343-4.CrossRefPubMed
20.
go back to reference Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001, 357: 905-910. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001, 357: 905-910.
21.
go back to reference Bottorff MB: Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006, 97: 27C-31C. 10.1016/j.amjcard.2005.12.007.CrossRefPubMed Bottorff MB: Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006, 97: 27C-31C. 10.1016/j.amjcard.2005.12.007.CrossRefPubMed
Metadata
Title
Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial
Authors
Katie Jerzewski
Marc Ruel
Pierre Voisine
Michel R Le May
Alexander Kulik
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2013
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/1749-8090-8-172

Other articles of this Issue 1/2013

Journal of Cardiothoracic Surgery 1/2013 Go to the issue